423 related articles for article (PubMed ID: 26824521)
1. Staufen1 Regulates Multiple Alternative Splicing Events either Positively or Negatively in DM1 Indicating Its Role as a Disease Modifier.
Bondy-Chorney E; Crawford Parks TE; Ravel-Chapuis A; Klinck R; Rocheleau L; Pelchat M; Chabot B; Jasmin BJ; Côté J
PLoS Genet; 2016 Jan; 12(1):e1005827. PubMed ID: 26824521
[TBL] [Abstract][Full Text] [Related]
2. The RNA-binding protein Staufen1 is increased in DM1 skeletal muscle and promotes alternative pre-mRNA splicing.
Ravel-Chapuis A; Bélanger G; Yadava RS; Mahadevan MS; DesGroseillers L; Côté J; Jasmin BJ
J Cell Biol; 2012 Mar; 196(6):699-712. PubMed ID: 22431750
[TBL] [Abstract][Full Text] [Related]
3. Misregulation of calcium-handling proteins promotes hyperactivation of calcineurin-NFAT signaling in skeletal muscle of DM1 mice.
Ravel-Chapuis A; Bélanger G; Côté J; Michel RN; Jasmin BJ
Hum Mol Genet; 2017 Jun; 26(12):2192-2206. PubMed ID: 28369518
[TBL] [Abstract][Full Text] [Related]
4. Molecular mechanisms responsible for aberrant splicing of SERCA1 in myotonic dystrophy type 1.
Hino S; Kondo S; Sekiya H; Saito A; Kanemoto S; Murakami T; Chihara K; Aoki Y; Nakamori M; Takahashi MP; Imaizumi K
Hum Mol Genet; 2007 Dec; 16(23):2834-43. PubMed ID: 17728322
[TBL] [Abstract][Full Text] [Related]
5. Systemic Evaluation of Chimeric LNA/2'-O-Methyl Steric Blockers for Myotonic Dystrophy Type 1 Therapy.
Christou M; Wengel J; Sokratous K; Kyriacou K; Nikolaou G; Phylactou LA; Mastroyiannopoulos NP
Nucleic Acid Ther; 2020 Apr; 30(2):80-93. PubMed ID: 31873063
[TBL] [Abstract][Full Text] [Related]
6. In silico discovery of substituted pyrido[2,3-d]pyrimidines and pentamidine-like compounds with biological activity in myotonic dystrophy models.
González ÀL; Konieczny P; Llamusi B; Delgado-Pinar E; Borrell JI; Teixidó J; García-España E; Pérez-Alonso M; Estrada-Tejedor R; Artero R
PLoS One; 2017; 12(6):e0178931. PubMed ID: 28582438
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of Staufen1 in DM1 mouse skeletal muscle exacerbates dystrophic and atrophic features.
Crawford Parks TE; Marcellus KA; Péladeau C; Jasmin BJ; Ravel-Chapuis A
Hum Mol Genet; 2020 Aug; 29(13):2185-2199. PubMed ID: 32504084
[TBL] [Abstract][Full Text] [Related]
8. Muscleblind-like 1 knockout mice reveal novel splicing defects in the myotonic dystrophy brain.
Suenaga K; Lee KY; Nakamori M; Tatsumi Y; Takahashi MP; Fujimura H; Jinnai K; Yoshikawa H; Du H; Ares M; Swanson MS; Kimura T
PLoS One; 2012; 7(3):e33218. PubMed ID: 22427994
[TBL] [Abstract][Full Text] [Related]
9. Staufen1 impairs stress granule formation in skeletal muscle cells from myotonic dystrophy type 1 patients.
Ravel-Chapuis A; Klein Gunnewiek A; Bélanger G; Crawford Parks TE; Côté J; Jasmin BJ
Mol Biol Cell; 2016 Jun; 27(11):1728-39. PubMed ID: 27030674
[TBL] [Abstract][Full Text] [Related]
10. Sense and Antisense DMPK RNA Foci Accumulate in DM1 Tissues during Development.
Michel L; Huguet-Lachon A; Gourdon G
PLoS One; 2015; 10(9):e0137620. PubMed ID: 26339785
[TBL] [Abstract][Full Text] [Related]
11. DM1 CTG expansions affect insulin receptor isoforms expression in various tissues of transgenic mice.
Guiraud-Dogan C; Huguet A; Gomes-Pereira M; Brisson E; Bassez G; Junien C; Gourdon G
Biochim Biophys Acta; 2007 Dec; 1772(11-12):1183-91. PubMed ID: 17950578
[TBL] [Abstract][Full Text] [Related]
12. Short antisense-locked nucleic acids (all-LNAs) correct alternative splicing abnormalities in myotonic dystrophy.
Wojtkowiak-Szlachcic A; Taylor K; Stepniak-Konieczna E; Sznajder LJ; Mykowska A; Sroka J; Thornton CA; Sobczak K
Nucleic Acids Res; 2015 Mar; 43(6):3318-31. PubMed ID: 25753670
[TBL] [Abstract][Full Text] [Related]
13. Reduced cytoplasmic MBNL1 is an early event in a brain-specific mouse model of myotonic dystrophy.
Wang PY; Lin YM; Wang LH; Kuo TY; Cheng SJ; Wang GS
Hum Mol Genet; 2017 Jun; 26(12):2247-2257. PubMed ID: 28369378
[TBL] [Abstract][Full Text] [Related]
14. Staufen1s role as a splicing factor and a disease modifier in Myotonic Dystrophy Type I.
Bondy-Chorney E; Crawford Parks TE; Ravel-Chapuis A; Jasmin BJ; Côté J
Rare Dis; 2016; 4(1):e1225644. PubMed ID: 27695661
[TBL] [Abstract][Full Text] [Related]
15. MBNL1 is the primary determinant of focus formation and aberrant insulin receptor splicing in DM1.
Dansithong W; Paul S; Comai L; Reddy S
J Biol Chem; 2005 Feb; 280(7):5773-80. PubMed ID: 15546872
[TBL] [Abstract][Full Text] [Related]
16. A flow cytometry-based screen identifies MBNL1 modulators that rescue splicing defects in myotonic dystrophy type I.
Zhang F; Bodycombe NE; Haskell KM; Sun YL; Wang ET; Morris CA; Jones LH; Wood LD; Pletcher MT
Hum Mol Genet; 2017 Aug; 26(16):3056-3068. PubMed ID: 28535287
[TBL] [Abstract][Full Text] [Related]
17. (CTG)n repeat-mediated dysregulation of MBNL1 and MBNL2 expression during myogenesis in DM1 occurs already at the myoblast stage.
André LM; van Cruchten RTP; Willemse M; Wansink DG
PLoS One; 2019; 14(5):e0217317. PubMed ID: 31116797
[TBL] [Abstract][Full Text] [Related]
18. Quantitative Methods to Monitor RNA Biomarkers in Myotonic Dystrophy.
Wojciechowska M; Sobczak K; Kozlowski P; Sedehizadeh S; Wojtkowiak-Szlachcic A; Czubak K; Markus R; Lusakowska A; Kaminska A; Brook JD
Sci Rep; 2018 Apr; 8(1):5885. PubMed ID: 29651162
[TBL] [Abstract][Full Text] [Related]
19. Developmental insights into the pathology of and therapeutic strategies for DM1: Back to the basics.
Chau A; Kalsotra A
Dev Dyn; 2015 Mar; 244(3):377-90. PubMed ID: 25504326
[TBL] [Abstract][Full Text] [Related]
20. AON-induced splice-switching and DMPK pre-mRNA degradation as potential therapeutic approaches for Myotonic Dystrophy type 1.
Stepniak-Konieczna E; Konieczny P; Cywoniuk P; Dluzewska J; Sobczak K
Nucleic Acids Res; 2020 Mar; 48(5):2531-2543. PubMed ID: 31965181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
